---
title: "辉瑞：诺和诺德的提议 “不过是向 Metsera 支付一种老式贿赂”，意在阻止竞争，这损害了辉瑞以及依赖改变生命的药物的消费者的利益。"
description: "辉瑞：诺和诺德的提议 “不过是向 Metsera 支付一种老式贿赂”，意在阻止竞争，这损害了辉瑞以及依赖改变生命的药物的消费者的利益。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263812219.md"
published_at: "2025-10-31T21:52:51.000Z"
---

# 辉瑞：诺和诺德的提议 “不过是向 Metsera 支付一种老式贿赂”，意在阻止竞争，这损害了辉瑞以及依赖改变生命的药物的消费者的利益。

辉瑞：诺和诺德的提议 “不过是向 Metsera 支付一种老式贿赂”，意在阻止竞争，这损害了辉瑞以及依赖改变生命的药物的消费者的利益。

### Related Stocks

- [PFE.US - 辉瑞](https://longbridge.com/zh-CN/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/zh-CN/news/276314777.md) |
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/zh-CN/news/276252273.md) |
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/zh-CN/news/276056741.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/zh-CN/news/276442777.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-CN/news/276447697.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。